TNSN99079A1 - Derives de quinazolinamines nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant - Google Patents

Derives de quinazolinamines nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant

Info

Publication number
TNSN99079A1
TNSN99079A1 TNTNSN99079A TNSN99079A TNSN99079A1 TN SN99079 A1 TNSN99079 A1 TN SN99079A1 TN TNSN99079 A TNTNSN99079 A TN TNSN99079A TN SN99079 A TNSN99079 A TN SN99079A TN SN99079 A1 TNSN99079 A1 TN SN99079A1
Authority
TN
Tunisia
Prior art keywords
preparation
pharmaceutical compositions
compositions containing
new
quinazolinamine
Prior art date
Application number
TNTNSN99079A
Other languages
English (en)
Inventor
John Meldrum Allen Douglas
Norris Timothy
William Raggon Jeffrey
Paul Santafianos Dinos
Mysore Shanker Ravi
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TNSN99079A1 publication Critical patent/TNSN99079A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENTION CONCERNE LES FORMES ANHYDRES ET HYDRATEES DU MESYLATE DE N-(3-ETHYNYLPHENYL)-6,7-BIS(2-METHOXYETHOXY)-4-QUINAZOLINAMINE. ELLE CONCERNE EGALEMENT UN PROCEDE POUR LEUR PREPARATION ET DES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT. APPLICATION : UTILISATION DE CES COMPOSES ET COMPOSITIONS POUR LE TRAITEMENT DE TROUBLES HYPERPROLIFERATIFS, TELS QUE DES CANCERS.
TNTNSN99079A 1998-04-29 1999-04-28 Derives de quinazolinamines nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant TNSN99079A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8344198P 1998-04-29 1998-04-29

Publications (1)

Publication Number Publication Date
TNSN99079A1 true TNSN99079A1 (fr) 2005-11-10

Family

ID=22178359

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN99079A TNSN99079A1 (fr) 1998-04-29 1999-04-28 Derives de quinazolinamines nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant

Country Status (42)

Country Link
EP (1) EP1076652B1 (fr)
JP (1) JP4652569B2 (fr)
KR (1) KR100668412B1 (fr)
CN (2) CN1298396A (fr)
AP (1) AP1252A (fr)
AR (1) AR018201A1 (fr)
AT (1) ATE295839T1 (fr)
AU (1) AU759691C (fr)
BR (1) BR9910025A (fr)
CA (1) CA2330447C (fr)
CO (1) CO5060467A1 (fr)
CZ (1) CZ298230B6 (fr)
DE (1) DE69925366T2 (fr)
DZ (1) DZ2777A1 (fr)
EA (1) EA002836B1 (fr)
EG (1) EG24000A (fr)
ES (1) ES2238825T3 (fr)
GT (1) GT199900063A (fr)
HK (1) HK1037180A1 (fr)
HN (1) HN1999000057A (fr)
HU (1) HU227569B1 (fr)
ID (1) ID27198A (fr)
IL (1) IL139172A0 (fr)
MA (1) MA26624A1 (fr)
ME (1) MEP42008A (fr)
MX (1) MXPA00010610A (fr)
MY (1) MY136033A (fr)
NO (1) NO317301B1 (fr)
NZ (1) NZ508154A (fr)
OA (1) OA11769A (fr)
PA (1) PA8471001A1 (fr)
PE (1) PE20000441A1 (fr)
PL (1) PL196940B1 (fr)
RS (1) RS50081B (fr)
SA (1) SA99200216B1 (fr)
TN (1) TNSN99079A1 (fr)
TR (1) TR200003166T2 (fr)
TW (1) TWI248437B (fr)
UA (1) UA60363C2 (fr)
UY (1) UY26099A1 (fr)
WO (1) WO1999055683A1 (fr)
ZA (1) ZA992972B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
YU13200A (sh) 1999-03-31 2002-10-18 Pfizer Products Inc. Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja
US7087613B2 (en) 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
UA74803C2 (uk) * 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
UA73993C2 (uk) * 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
WO2003000188A2 (fr) 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Nouvelles quinazolines et leur utilisation
US7078409B2 (en) 2002-03-28 2006-07-18 Beta Pharma, Inc. Fused quinazoline derivatives useful as tyrosine kinase inhibitors
GB0223854D0 (en) * 2002-10-12 2002-11-20 Astrazeneca Ab Therapeutic treatment
US7148231B2 (en) * 2003-02-17 2006-12-12 Hoffmann-La Roche Inc. [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)amine hydrochloride polymorph
AU2004291709C1 (en) 2003-05-30 2010-03-11 Astrazeneca Uk Limited Process
WO2004111055A1 (fr) 2003-06-10 2004-12-23 F. Hoffmann-La Roche Ag Derives de 1,3,4-triaza-phenalene et de 1,3,4,6-tetra-azaphenalene
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
BRPI0510717B8 (pt) 2004-05-06 2021-05-25 Bioresponse Llc uso de 3,3' diindolilmetano (dim) ou 2-(indol-3-ilmetil)-3,3´-diindolilmetano (ltr)
WO2006083458A2 (fr) 2004-12-30 2006-08-10 Bioresponse Llc Utilisation d'indoles lies au diindolylmethane dans le traitement et la prevention d'etats associes au virus respiratoire syncytial
CN101547910A (zh) 2006-07-28 2009-09-30 合成纤维有限公司 结晶埃罗替尼
BRPI0717753B1 (pt) 2006-10-27 2022-04-12 Bioresponse, Llc Uso de uma composição compreendendo 50-250 mg de um ou mais indóis relacionados com dim e um ou mais agentes anti-protozoários, e, composição
AU2008235274B2 (en) * 2007-04-04 2013-04-18 Cipla Limited Process for preparation of erlotinib and its pharmaceutically acceptable salts
EP2162444B1 (fr) 2007-07-11 2014-06-04 Hetero Drugs Limited Procédé amélioré de préparation de l'hydrochlorate d'erlotinibe
US20100136116A1 (en) 2007-08-17 2010-06-03 Hetero Drugs Limited Novel hydrated form of erlotinib free base and a process for preparation of erlotinib hydrochloride polymorph form a substantially free of polymorph form b
KR101132937B1 (ko) * 2008-10-01 2012-04-06 주식회사종근당 Ｎ-(3-에티닐페닐)-6,7-비스(2-메톡시에톡시)-4-퀴나졸린아민 납실레이트 염
US8440823B2 (en) 2009-03-26 2013-05-14 Ranbaxy Laboratories Limited Process for the preparation of erlotinib or its pharmaceutically acceptable salts thereof
WO2011068404A2 (fr) 2009-12-02 2011-06-09 Ultimorphix Technologies B.V. Administration par inhalation de sel de mésylate de n-(3-éthynylphénylamino)-6,7-bis(2-méthoxyéthoxy)-4-quinazolinamine
DE202010006543U1 (de) 2010-05-07 2010-09-09 Ratiopharm Gmbh Erlotinibresinat
HU230483B1 (hu) 2011-10-10 2016-07-28 Egis Gyógyszergyár Nyrt. Erlotinib sók
US9593083B2 (en) 2012-09-04 2017-03-14 Shilpa Medicare Limited Crystalline erlotinib hydrochloride process

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ243082A (en) * 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
JP2994165B2 (ja) * 1992-06-26 1999-12-27 ゼネカ・リミテッド キナゾリン誘導体、その製造法および該キナゾリン誘導体を含有する抗癌作用を得るための医薬調剤
GB9323290D0 (en) * 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
EP1110953B1 (fr) * 1995-03-30 2009-10-28 Pfizer Products Inc. Dérivés de quinazolinone
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines

Also Published As

Publication number Publication date
IL139172A0 (en) 2001-11-25
EA200001112A1 (ru) 2001-04-23
DE69925366T2 (de) 2006-03-09
DZ2777A1 (fr) 2003-12-01
SA99200216B1 (ar) 2006-06-04
CN1298396A (zh) 2001-06-06
UY26099A1 (es) 2001-12-28
DE69925366D1 (de) 2005-06-23
BR9910025A (pt) 2000-12-26
OA11769A (en) 2005-07-25
NO20005453L (no) 2000-12-20
JP2002513009A (ja) 2002-05-08
CZ20003974A3 (en) 2001-05-16
CA2330447C (fr) 2009-06-30
HU227569B1 (en) 2011-08-29
NO317301B1 (no) 2004-10-04
EP1076652B1 (fr) 2005-05-18
PA8471001A1 (es) 2000-09-29
CN101219999A (zh) 2008-07-16
UA60363C2 (uk) 2003-10-15
KR20010078710A (ko) 2001-08-21
HUP0101818A3 (en) 2002-05-28
RS50081B (sr) 2009-01-22
CZ298230B6 (cs) 2007-08-01
AP1252A (en) 2004-02-25
ID27198A (id) 2001-03-08
AP9901523A0 (en) 1999-06-30
NO20005453D0 (no) 2000-10-27
MA26624A1 (fr) 2004-12-20
AR018201A1 (es) 2001-10-31
PL196940B1 (pl) 2008-02-29
CA2330447A1 (fr) 1999-11-04
AU759691C (en) 2004-04-29
CO5060467A1 (es) 2001-07-30
ZA992972B (en) 2000-10-30
MY136033A (en) 2008-07-31
TR200003166T2 (tr) 2001-02-21
KR100668412B1 (ko) 2007-01-12
HUP0101818A1 (hu) 2002-03-28
EP1076652A1 (fr) 2001-02-21
JP4652569B2 (ja) 2011-03-16
EA002836B1 (ru) 2002-10-31
HK1037180A1 (en) 2002-02-01
WO1999055683A1 (fr) 1999-11-04
PL343766A1 (en) 2001-09-10
MXPA00010610A (es) 2002-07-02
NZ508154A (en) 2003-07-25
PE20000441A1 (es) 2000-05-23
ES2238825T3 (es) 2005-09-01
EG24000A (en) 2008-03-19
MEP42008A (en) 2011-02-10
AU759691B2 (en) 2003-04-17
HN1999000057A (es) 1999-09-29
AU2850999A (en) 1999-11-16
TWI248437B (en) 2006-02-01
ATE295839T1 (de) 2005-06-15
YU66100A (sh) 2003-07-07
GT199900063A (es) 2000-10-20

Similar Documents

Publication Publication Date Title
TNSN99079A1 (fr) Derives de quinazolinamines nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN97040A1 (fr) Compositions pharmaceutiques mixtes pour le traitement de l'osteoporose, et procede pour leur preparation.
TNSN97144A1 (fr) Derives 6,6-heterobicycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99162A1 (fr) Derives de quinoleine-2-one a substituant alcynyle nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN97192A1 (fr) Derives de pyrimidine bicycliques condenses, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN99126A1 (fr) Pyrrolopyrimidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99169A1 (fr) Derives de 4,4-biarylpiperidine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99106A1 (fr) Derives d'isothiazole nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN99236A1 (fr) Derives bicycliques substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
ATE334668T1 (de) Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
TNSN99125A1 (fr) Pyrrolo(2,3-d) pyrimidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98182A1 (fr) Agonistes de prostaglandines nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98084A1 (fr) Derives de macrolides substitues en position c-4
TNSN98238A1 (fr) Macrolides nouveaux
TNSN99170A1 (fr) Derives de tetrahydroquinoleine substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN01017A1 (fr) Compositions comprenant un antibiotique azalide, et procedes pour leur preparation
TNSN98035A1 (fr) Atropisomeres de 3-aryl-4(3h)-quinazolinones, procede pour leur preparation et compositions les contenant
MA26629A1 (fr) Preparation pharmaceutique de sildénafil a delitement oral, et procede pour sa production
TNSN99155A1 (fr) 1-aryl-3-arylmethyl-1,8-naphtyridine-4(1h)-ones nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99147A1 (fr) Procede d'emulsification
TNSN97087A1 (fr) 4(3h)-quinazolinones 2,3-disubstituees nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99031A1 (fr) Composes heterocycliques nouveaux inhibiteurs de romatases, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98127A1 (fr) Derives d'azetidinylpropylpiperidine , procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26741A1 (fr) Suspensions de ziprasidone nouvelles et procede pour leur preparation.
PT1060175E (pt) Inibidores de triptase